Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors

Last updated: January 17, 2025
Sponsor: VA Office of Research and Development
Overall Status: Active - Not Recruiting

Phase

3

Condition

Obesity

Aging

Diabetes Prevention

Treatment

Healthy Lifestyle

Lifestyle therapy

Metformin Hydrochloride

Clinical Study ID

NCT04221750
ENDA-007-19F
H-46970
  • Ages 65-85
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The continuing increase in prevalence of obesity in older adults including many older Veterans has become a major health concern. The clinical trial will test the central hypothesis that a multicomponent intervention consisting of lifestyle therapy (diet-induced weight loss and exercise training) plus metformin will be the most effective strategy for reversing sarcopenic obesity and frailty in older Veterans with obesity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • BMI = or > 30 kg/m2

  • Stable body weight (plus/minus 2 kg) during the past 6 months

  • Sedentary (regular exercise <1 h/wk or <2 x/wk for the last 6 months)

  • Willing to provide informed consent

Exclusion

Exclusion Criteria:

  • Any major chronic diseases, or any condition that would interfere with exercise ordietary restriction, or use of metformin, in which exercise, dietary restrictions,or metformin are contraindicated, or that would interfere with interpretation ofresults

  • Cardiopulmonary disease (e.g. recent MI, unstable angina, stroke) or unstabledisease (e.g., NYHA Class III or IV congestive heart failure, severe pulmonarydisease requiring steroid pills or the use of supplemental oxygen) that wouldcontraindicate exercise or dietary restriction

  • Severe orthopedic (e.g. awaiting joint replacement) and/or neuromuscular (e.g.multiple sclerosis, active rheumatoid arthritis) disease or impairments that wouldcontraindicate participation in exercise

  • Renal impairment as defined by an estimated glomerular filtration rate (eGFR of lessthan 30 mL/min/1.73 m2) in which metformin is contraindicated

  • Other significant co-morbid disease that would impair ability to participate in theexercise intervention (e.g. severe psychiatric disorder [e.g. bipolar,schizophrenia], excess alcohol use [>14 drinks per week])

  • Severe visual or hearing impairments that would interfere with following directions

  • Significant cognitive impairment, defined as a known diagnosis of dementia orpositive screening test for dementia using the Mini-Mental State Exam (i.e. MMSEscore <24)69

  • Uncontrolled hypertension (BP>160/90 mm Hg)

  • History of malignancy during the past 5 years (except non-melanoma skin cancers)

  • Current use of bone acting drugs (e.g. use of estrogen, or androgen containingcompound,raloxifene, calcitonin, parathyroid hormone during the past year orbisphosphonates during the last two years)

  • Osteoporosis (T-score -2.5 and below on hip or spine scan) or history of fragilityfractures

  • Known history of diabetes mellitus or any of the following:

  • fasting blood glucose of 126 mg/dl, 2-h blood glucose 200 mg/dl in the OGTT, orHbA1c of 6.5% or >

  • Terminal illness with life expectancy less than 12 months, as determined by aphysician

  • Use of any drugs or natural products designed to induce weight loss within pastthree months

  • History of excessive alcohol consumption (e.g. 8 or more drinks a week for women and 15 or more drinks a week for men)

  • Positive exercise stress test for ischemia or any indication for early terminationof exercise stress testing

  • Taking metformin or any other glucose lowering drug

  • Lives outside of the study site or is planning to move out of the area in the next 2years

Study Design

Total Participants: 114
Treatment Group(s): 5
Primary Treatment: Healthy Lifestyle
Phase: 3
Study Start date:
May 14, 2021
Estimated Completion Date:
September 30, 2027

Study Description

The growing prevalence of obesity in older adults including many older Veterans, has become a major concern in the US already strained health care system in general and in the VA in particular. In older adults, obesity exacerbates the age-related decline in physical function resulting in frailty, decrease in quality of life, loss of independence, and increase in nursing home admissions. The investigators' group demonstrated that weight loss from lifestyle therapy improves physical function and ameliorates frailty but the improvement was modest at best and most obese older adults remained frail. More importantly, there are concerns that the weight-loss induced loss of muscle and bone mass could worsen underlying age-related sarcopenia and osteopenia in the subset of frail obese elderly. Metformin, a biguanide, is a widely available drug used as first line treatment of type 2 diabetes. Animal studies suggest that metformin improves health span and increases lifespan, hence may represent a novel intervention for frailty. Because metformin reduces cellular senescence and senescence-associated phenotype (SASP), it is believed to retard accelerated aging most especially in older adults with obesity. The objective is to conduct a head-head comparative efficacy, placebo controlled, randomized controlled trial to test the hypothesis that lifestyle therapy + metformin for six months will be more effective than lifestyle therapy alone or metformin alone in improving physical function and preventing the weight loss-induced reduction in muscle and bone mass in obese (BMI > 30 kg/m2) older (age 65 years) Veterans with physical frailty.

Connect with a study center

  • Michael E. DeBakey VA Medical Center, Houston, TX

    Houston, Texas 77030-4211
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.